media – Page 502 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Autism Screening App on iOS by Duke University

With parents' permission, the new app enables a smartphones' front camera to record videos of a child's reactions while watching a movie with the phone place facing them. This is done obtain autism risk behaviors such as attention, emotions and patterns. The recorded response is then sent to the research survey, where behavioral automatic coding software keeps track on the movements on the video and marks on the child's face after which their attention and emotions are measured.
- Source: Ddu
- 564
- June 7, 2018
autism mHealth Researches
FDA Recalls HeartMate device Manufactured by Abbott

This will be the second recall on a heart device this month Medtronic’s Heartware device and accessories was recalled a few days ago. This comes after Abbott issued a patch to negate cybersecurity issues 350,000 remote monitoring systems and pacemakers.
- Source: Ddu
- 710
- June 7, 2018
Abbott Company Insight heart failure medical device
Hospira Inc. Recalls Opioid Antidote Naloxone

According to the FDA, if the antidote drugs are used on a patient, they could suffer from “allergic reactions, local irritation” and a wide number of cardiovascular issues, including restriction of blood supply to tissues. The FDA stated that there has not yet been any reports of patient harm from Naloxone.
- Source: Ddu
- 611
- June 7, 2018
Company Insights FDA opioid
Apple to launch new Health Record API for developers

This week Apple announced that researchers and app developers can now have access to a Health Record API (Application Programming Interface) to develop applications, with the permission to use the patient’s data to provide them with easy access to health records.
- Source: drugdu
- 709
- June 7, 2018
Company Insight digital health mHealth
Smartphone Video Based App for TB

A research team from John Hopkins University School of Medicine created a cost-effective and patient-centric smartphone video-based app, which would substitute the daily in-person visits by a healthcare worker required for TB therapy, known as DOT (Directly Observed Therapy).
- Source: Ddu
- 793
- June 7, 2018
mHealth Researches tuberculosis
New Male Contraceptive Pill With No Side Effects

At present, condoms and vasectomy are the only birth control methods available for men. Even though many male hormonal drugs target the production of sperm, they also affect the natural hormones in men.
- Source: Ddu
- 1,218
- June 7, 2018
Clinical Trials contraceptive drugs Researches
Blood Test to Predict Drug Activity Against Breast Cancer

At present, breast cancer patients need to wait for nearly two to three months to find out via a scan whether palbociclib is working. This new test could detect the circulating tumor DNA which enters the bloodstream. By measuring and comparing PIK3CA levels in a blood test before and 15 post palbociclib therapy, one could predict the effectiveness of the drug.
- Source: Ddu
- 887
- June 7, 2018
blood test breast cancer Researches
Therapy Against Progeria

After conducting a clinical trial study at Boston Children’s Hospital, scientists from Brown University recommended that a lonafarnib therapy could increase the survival rate of progeria patients. But the mode of action of lonafarnib is still uncertain.
- Source: Ddu
- 534
- June 7, 2018
progeria rare diseases Researches
IPO Filed by Translate for Undertaking Fibrosis Treatment Trial

An IPO for raising USD 115 million from public investors has been filed by Translate Bio. Proceeds garnered from the IPO will be used by Translate to trial an mRNA candidate designed to allow cystic fibrosis patients produce CTFR proteins.
- Source: Ddu
- 579
- June 6, 2018
Clinical Trials cystic fibrosis
Lynparza and Zytiga Combo Effective Against Prostate Cancer

Along with new drug partner Merck, the British drugmaker displayed results showing that adding Lynparza to Johnson & Johnson prostate cancer fighter Zytiga was a more potent disease-fighter than Zytiga alone. As compared to a time-frame of 8.2 months for solo Zytiga, the combo effectively prevented disease progression for 13.8 months.
- Source: Ddu
- 764
- June 6, 2018
AstraZeneca Clinical Trials Company Insight prostate cancer

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.